19 May 2013
Keywords: xoma, start, raptiva, trial, psoriatic, arthritis, partner
Article | 10 February 2003
Xoma and partner Genentech have initiated a Phase II trial of itsICAM-1 blocker Raptiva (efalizumab) in patients with active and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 February 2003
10 February 2003
17 May 2013
© 2013 thepharmaletter.com